Navigation Links
SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
Date:3/12/2013

JERUSALEM, Israel, March 12, 2013 /PRNewswire/ --

SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of patent-pending voice recognition technology that reduces the risks of errors during the administration of prescription medications, announced today that the company has acquired breakthrough Quickool technology enabling individuals to self-administer pain free injections.

SafeCode Drug Technologies acquired Quickool and EasyJet technology from Sindolor Medical Ltd., an Israel-based medical technologies development company.

The technologies enable individuals to safely and painlessly administer injections or blood lancing, by quickly cooling the site of the injection immediately prior to the piercing of the skin. The technology is particularly useful for patients with diabetes who need to test blood-sugar levels or inject themselves regularly with insulin.  

In addition, the technology has several other useful applications. SafeCode intends to publish additional announcements regarding Quickool and EasyJet technologies in the coming months.

"The acquisition of additional marketable technologies adds significant value to SafeCode's existing product line," said Joel Klopfer , Chief Executive Officer of SafeCode Drug Technologies.  "SafeCode's voice activated technology simplifies the administration of prescription medication, and the technology acquired from Sindolor Medical provides similar benefit."

"Making the administration of medicines and blood tests easier and painless has the potential to save lives, by reducing the chances of potentially life-threatening errors," Klopfer added.

About SafeCode Drug Technologies

SafeCode Drug Technologies is the developer of a patent-pending voice recognition technology that provides an essential degree of security that can effectively prevent unauthorized administration of a prescription medication.  

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated.  SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact:

Joel Klopfer
Joel.Klofer1@gmail.com
+9722-5021322


'/>"/>
SOURCE Safecode Drug Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SafeCode Drug Technologies Corp Signs an Agreement With INTOVISION PRODUCT DEVELOPMENT & DESIGN (An Israeli Product Development Co) to Manufacturers the Worlds First Voice Recognition Drug Safety Application Prototype
2. SafeCode Drug Technologies Corporation Identifies the Technology Group to Commence and Develop the Worlds First Prototype for its Next Generation Application for Drug Safety Administration
3. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
4. SafeCode Drug Technologies Corp. in Negotiations With Manufacturers to Develop Prototype
5. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
6. Xyntek-Antares & ESS Technologies to Unveil New Ultra Compact TaskMate(R) Robotic Case Erector / Loader with Track & Trace at Interphex 2013
7. Cylene Pharmaceuticals and TetraGene Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
8. Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc.
9. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
10. Particle Sciences and NETZSCH Premier Technologies Enter into Collaboration
11. Animas Development of a First-Generation Closed Loop Insulin Delivery System Progresses With Data Presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):